Biovail shares drop as rival seeks to sell generic antidepressant
295825
TORONTO - Shares of Biovail Corp. fell through their one-year low on Wednesday after the firm said a competitor is seeking US approval for a generic version of the pharmaceutical company&#39;s top product.
44221
Novartis AG  cut its full-year results outlook as generic competition pressured sales of a key blood-pressure drug, and said U.S. regulators had delayed the approval process for an important cancer treatment.
268315
Pfizer Inc.  on Wednesday reported lower-than-expected quarterly earnings on competition with generics and a surprisingly big 13 percent decline in sales of its best-selling Lipitor cholesterol fighter.
20825
Shares of Indianapolis-based drugmaker  Eli Lilly and Co. LLY.N, maker of antidepressant drug Prozac,  nudged nearly 1 percent lower on Friday.
653549
Shares of Wyeth WYE.N and Pfizer  Inc. PFE.N fell on Monday after Merrill Lynch downgraded the  drugmakers and U.K. regulators issued tougher warnings on the  type of popular depression drugs sold by the companies.
410890
AstraZeneca shares have fallen more than 6 percent after a US medical panel recommended regulators reject its anti-clotting pill Exanta, a key product for the company&#39;s future growth.
691847
Biotechnology stocks moved lower Friday as Genentech Inc. and OSI Pharmaceuticals lost value despite an earlier-than-expected approval of their lung cancer drug Tarceva.
426995
AstraZeneca Plc suffered its third  setback in two months on Friday as lung cancer drug Iressa  failed to help patients live longer in a major clinical trial,  sending its shares down more than 8 percent.
741470
Shares of biotech company Biomira Inc. soared as it and a development partner, German drug maker Merck KGaA, reported Friday that the median survival in a study involving a lung cancer vaccine has yet to be reached after 23 months in a subset of patients.
109512
NEW YORK -- Syneron Medical Ltd. stock fell Tuesday after the US Food and Drug Administration delayed approval of the medical device maker&#39;s cellulite product.
373857
Leading shares closed the session under pressure, hit by weakness in heavyweight pharmas after AstraZeneca admitted a key cancer drug had failed tests and poor trading in New York, dealers said.
750028
Shares in Schering dropped on Friday  after the German drugmaker said U.S. regulators needed more  information to approve its key Bonefos drug for use in  preventing bone tumors in breast cancer patients.
153503
Swiss drugmaker Novartis AG   missed forecasts with a 42 percent drop in  fourth-quarter net profit, hit by generic competition and a  one-off restructuring charge, sending its shares lower.
73972
Shares of Syneron Medical Ltd., a maker of cosmetic medical devices, plunged 20 percent Tuesday morning following regulators&#39; rejection of its application for a cellulite-smoothing device.
657789
Bristol-Myers Squibb, reeling from the incursion of a generic competitor to its top-selling drug Plavix, lowered its earnings forecast for the year.
168451
Shares of Kos Pharmaceuticals Inc. sank 13 percent in heavy trading Thursday after an investment bank suggested that the company&#39;s key cholesterol drug may face generic competition as soon as April.
372947
Stocks of branded and generic drug makers closed down a bit Tuesday as clinical study results mixed with merger updates. One of the big winners on the day was Nektar Therapeutics, on news that Exubera, the